戈沙妥珠单抗在转移性三阴性乳腺癌及其他实体瘤中的群体药代动力学
基于529例mTNBC或其他实体瘤患者的两项大型临床试验数据,构建SG、游离SN-38及总抗体的群体药代动力学模型,评估协变量对暴露的影响。结果显示轻中度肾功能损害、轻度肝损害、年龄、性别、基线白蛋白、肿瘤类型、UGT1A1基因型或Trop-2表达均无临床相关影响,支持10 mg/kg的已批准给药方案,无需基于评估协变量调整剂量。
要点
- SG、游离SN-38和总抗体的药代动力学均可用二室模型描述,清除率和分布容积按体重幂函数缩放。
- 轻中度肾功能损害、轻度肝损害等评估协变量对三种分析物的暴露均无临床相关影响。
- 结果支持SG按10 mg/kg在第1、8天静脉输注的已批准方案,无需基于协变量调整剂量。
核心结论
- 群体药代动力学分析支持SG的已批准给药方案10 mg/kg(21天周期第1、8天静脉输注),未发现基于评估协变量或疾病特征需要调整剂量的依据。
研究设计与样本
- 基于两项大型临床试验(NCT01631552;ASCENT,NCT02574455)中529例mTNBC或其他实体瘤患者的数据,采用非线性混合效应模型构建SG、游离SN-38和总抗体的群体药代动力学模型。
主要发现
- SG、游离SN-38和总抗体的药代动力学均以二室模型描述,清除率和分布容积采用基于体重的缩放指数估计。
- SG的典型清除率估计为0.133 L/h,稳态分布容积为3.68 L;总抗体的典型清除率为0.0164 L/h,稳态分布容积为4.26 L。
- 轻中度肾功能损害、轻度肝损害、年龄、性别、基线白蛋白水平、肿瘤类型、UGT1A1基因型或Trop-2表达对三种分析物的暴露均无临床相关影响。
临床怎么用
- 临床可按已批准的10 mg/kg方案(21天周期第1、8天静脉输注)使用SG,无需基于评估的协变量或疾病特征进行剂量调整。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Sacituzumab govitecan (SG) is an antibody-drug conjugate composed of an antibody with affinity for Trop-2 coupled to SN-38 via hydrolyzable linker. SG is approved for patients with metastatic triple-negative breast cancer (mTNBC) who have received two or more prior chemotherapies (at least one in a metastatic setting) and for patients with pretreated hormone receptor positive (HR+)/human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer. METHODS: In these analyses, the pharmacokinetics of SG, free SN-38, and total antibody (tAB) were characterized using data from 529 patients with mTNBC or other solid tumors across two large clinical trials (NCT01631552; ASCENT, NCT02574455). Three population pharmacokinetic models were constructed using non-linear mixed-effects modeling; clinically relevant covariates were evaluated to assess their impact on exposure. Models for SG and tAB were developed independently whereas free SN-38 was sequentially generated via a first-order release process from SG. RESULTS: Pharmacokinetics of the three analytes were each described by a two-compartment model with estimated body weight-based scaling exponents for clearance and volume. Typical parameter estimates for clearance and steady-state volume of distribution were 0.133 L/h and 3.68 L for SG and 0.0164 L/h and 4.26 L for tAB, respectively. Mild-to-moderate renal impairment, mild hepatic impairment, age, sex, baseline albumin level, tumor type, UGT1A1 genotype, or Trop-2 expression did not have a clinically relevant impact on exposure for any of the three analytes. CONCLUSIONS: These analyses support the approved SG dosing regimen of 10 mg/kg as intravenous infusion on days 1 and 8 of 21-day cycles and did not identify a need for dose adjustment based on evaluated covariates or disease characteristics.
引用
- Sathe AG, Singh I, Singh P, et al. Population Pharmacokinetics of Sacituzumab Govitecan in Patients with Metastatic Triple-Negative Breast Cancer and Other Solid Tumors. Clin Pharmacokinet. 2024. PMID: 38578394. doi:10.1007/s40262-024-01366-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。